Halozyme Therapeutics is a biopharmaceutical company that develops, manufactures, and commercializes drug delivery technologies and combination products to facilitate subcutaneous administration of injectable drugs. The company's core technology, ENHANZE, utilizes the proprietary enzyme rHuPH20 to enable the rapid subcutaneous delivery of high-dose biologics and small molecules, converting intravenous infusions into shorter subcutaneous injections. Halozyme licenses this technology to major pharmaceutical partners, including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai, Acumen, Merus, and Skye Bioscience. The company also develops Hypercon and Surf Bio technologies for hyperconcentrated biologic formulations and manufactures pressure-assisted auto-injector devices under brands such as VIBEX and Vai. Its proprietary commercial portfolio includes Hylenex, a hyaluronidase injection, and XYOSTED, an auto-injector product. Halozyme generates revenue through licensing fees, milestone payments, royalties, and the sale of bulk rHuPH20 and finished products.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage halozyme.com
Sector Healthcare IR page ir.halozyme.com/overview/default.aspx
Tags
drug delivery, subcutaneous injection, auto-injectors, hyaluronidase, biologics, microparticle technology, enzyme technology, parenteral delivery, combination products, ENHANZE, rHuPH20, Hypercon, Surf Bio, Aerocon, Hylenex, XYOSTED, VIBEX, VIBEX QuickShot, Vai, Elektrofi, Halozyme Hypercon
Press page halozyme.com/news

Metrics

Valuation  
Market cap $ 11.003B
Market cap (USD) $ 11.003B
P/E 24.14
PEG 1.49
P/BV -199.19
P/S 6.10
P/OCF 12.25
P/FCF 12.42
Dividend yield —
Turnover / mcap —
Returns  
ROE 153.6%
ROI 14.5%
ROIC 14.5%
Profit margin 22.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 16.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 66
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Revenue 1.397B 1.015B 829.253M 660.116M 443.31M 267.594M 195.992M 151.862M 316.613M 146.691M 135.057M 75.334M 54.799M 42.325M 56.086M 13.624M 13.671M 8.764M 3.8M — —
Net profit 316.889M 444.091M 281.594M 202.129M 402.71M 129.085M -72.24M -80.33M 62.971M -103.023M -32.231M -68.375M -83.479M -53.552M -19.77M -53.242M -58.361M -48.654M -23.896M -14.752M -13.275M
Free cash flow 644.588M 468.368M 373.277M 235.3M 297.983M 52.95M -89.463M -54.163M 132.703M -53.52M -39.443M -48.886M -51.637M -65.742M -35.179M -46.032M -41.609M -36.534M -2.513M 6.715M -13.347M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Share price 67.3 47.81 36.96 56.9 40.21 42.71 17.73 14.63 20.26 9.88 17.33 9.65 14.99 6.71 8 — 4.38 4.38 7 1.25 —
Price performance 12m 0.41 0.29 -0.35 0.42 -0.06 1.41 0.21 -0.28 1.05 -0.43 0.8 -0.36 1.23 -0.16 — — 0 -0.37 4.6 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 15.7M 22.1M 30M 59.4M 97.7M 91M 231M 233M 288M 426M
↳ YoY growth -51.6% +41.2% +35.6% +98.1% +64.4% -6.9% +154.0% +0.9% +23.6% +47.9%
↳ 5y CAGR +47.3% +7.1% +27.0% +45.4% +24.7% +42.1% +59.9% +50.7% +37.1% +34.3%
Borrowings, current (USD) 17.4M 77.2M 91.5M 19.5M 397M 89.4M 13.3M 0.00 0.00 0.00
Borrowings, non-current (USD) 199M 125M 34.9M 383M 0.00 787M 1.49B 1.5B 1.51B 2.14B
Lease liabilities (USD) — — 0.00 6.47M 4.87M 2.82M 34.8M 32.2M 30.7M 34.6M
Cash and deposits (USD) 66.8M 169M 57.9M 120M 148M 119M 234M 118M 116M 134M
Intangible assets (USD) — — — — — 0.00 547M 473M 402M 981M
Right-of-use assets (USD) — — 0.00 3.85M 3.3M 2M 40.5M 36.8M 34.2M 37.7M
Net debt (borrowings + leases - cash) (USD) 150M 33.6M 68.4M 289M 254M 761M 1.31B 1.41B 1.42B 2.04B
Cash flow detail
Operating cash flow (USD) -50.4M 134M -49.5M -85.4M 55.5M 299M 240M 389M 479M 652M
Purchases of property, plant and equipment (USD) -3.14M -1.35M -4.66M -4.04M -2.5M -1.46M -4.81M -15.3M -10.7M -6.97M
Change in receivables (cash effect) (USD) 16.7M -6.45M 11.6M -29.4M -38.3M 6.76M -83.9M -3.34M -74.2M -128M
Change in inventories (cash effect) (USD) -5.13M 9.48M -17.5M -6.73M -31.4M 7.37M -17.5M -26.9M -67.4M 2.55M
Change in payables (cash effect) (USD) -244,000 15.6M 5.7M 4.64M -41.2M 1.17M 24.5M -12.5M 47M 6.21M
Share buybacks (cash effect) (USD) — 0.00 0.00 -200M -150M -350M -200M -402M -250M -342M
Interest paid (cash effect) (USD) -3.89M -20.3M -16.9M -9.03M -6.53M -3.3M -6.11M -11.4M -10.6M -11.4M
Income taxes paid (cash effect) (USD) -1.44M -3.02M -220,000 -188,000 -180,000 -375,000 -16.2M -31.8M -80.6M -135M
Share-based compensation (USD) 25.6M 30.7M 35.7M 34.8M 17.2M 20.8M 24.4M 36.6M 43.4M 51.6M
Operating cash flow before change in receivables (USD) -67.1M 141M -61.1M -56M 93.7M 293M 324M 392M 553M 780M
Free cash flow (OCF - PPE - intangibles) (USD) -53.5M 133M -54.2M -89.5M 53M 298M 235M 373M 468M 645M
Income detail
Research and development expense (USD) 151M 151M 150M 141M 34.2M 35.7M 66.6M 76.4M 79M 81.5M
↳ 5y CAGR +21.2% +16.6% +9.2% +12.1% -18.2% -25.1% -15.1% -12.7% -10.9% +18.9%
Total comprehensive income (USD) -103M 62.5M -80.2M -71.7M 129M 402M 202M 273M 457M 295M
Comprehensive income to owners (USD) -103M 62.5M -80.2M -71.7M 129M 402M 202M 273M 457M 295M
Reported Feb 28, 2017 Feb 24, 2020 Feb 24, 2020 Feb 24, 2020 Feb 23, 2021 Aug 9, 2022 Feb 21, 2023 May 7, 2024 Feb 18, 2025 Feb 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 6, 2026

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer

SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE®, as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication does not include patients with oropharyngeal squamous cell carcinoma that is HPV-associated. It is the first approval of a dual-targeted therapy in this setting, simultaneously targeting epidermal growth factor receptor (EGFR)- and mesenchymal-epithelial transition (MET).

"This approval will further expand the reach of RYBREVANT FASPRO in a high unmet need population," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "We are pleased that our ENHANZE technology is helping bring a new subcutaneous treatment option to patients with advanced head and neck cancer."

November 6, 2026

SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on November 5th, 2026.

"Based on our analysis of CMS's final rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035. Importantly, there is also no projected impact on the Company's ability to execute new ENHANZE® partnership agreements where improving the patient treatment experience and competitive differentiation continue to be the top reasons ENHANZE is utilized," commented Dr. Helen Torley, President and Chief Executive Officer.

This outlook is supported by statements in the final rule affirming that orphan drug protections remain applicable and addressing the impacts of biosimilar entry on Program eligibility.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology, recently renamed as Aerocon™. Hypercon™ is microparticle technology with the potential to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Aerocon™ polymer-based hyperconcentration technology may further broaden the range of biologics that can be delivered subcutaneously. Together, we believe Hypercon™ and Aerocon™ technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

November 5, 2026

_Total Revenue Increased 39% YOY to $493 million
_Royalty Revenue Increased 44% YOY to $341 million

_Raising 2026 Financial Guidance Ranges:
__Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38%
__Royalty Revenue of $1.235 - $1.255 billion, YOY Growth of 42% - 45%
__Adjusted EBITDA of $1.240 - $1.290 billion, YOY Growth of 89% - 96%__1
__Non-GAAP Diluted EPS of $8.75 - $9.05, YOY Growth of 111% - 118%_1

Expanded ENHANZE_®_ Collaboration Agreements with Three Current Partners

Three ENHANZE_®_ Programs Advanced into Phase 1 Clinical Development

SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter ended September 30, 2026, and provided an update on its recent corporate activities.

"Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels," said Dr. Helen Torley, President and Chief Executive Officer. "In and post the quarter, we have achieved multiple milestones that expand our opportunity and diversify our revenue. During the quarter, we expanded our agreements with argenx and Incyte to include additional targets to be evaluated with ENHANZE. In October, we also signed an expanded agreement with Johnson & Johnson for one additional target. Three ENHANZE programs, one each with Pfizer, Incyte and argenx advanced into Phase 1 clinical development, bringing our total products in development to twelve."

Dr. Torley continued, "In October, we also achieved an important victory in protecting our intellectual property. The Dutch specialized patent court found that Merck is infringing one of our MDASE patents and granted an injunction prohibiting the launch of Keytruda Qlex in multiple European markets.  Our commitment to protecting the value of our innovations, growing royalties, continued partner expansion and growing pipeline demonstrates the power of Halozyme's compounding platform engine and positions us to deliver durable revenue well into the next decade."

"Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026," said Darren Snellgrove, Executive Vice President and Chief Financial Officer. "We also further strengthened our financial position with the successful completion of our $1.5 billion convertible notes, which enhances our flexibility to execute our disciplined capital allocation strategy. We completed $400 million in share repurchases this year while continuing to invest in our highest-return organic opportunities and maintaining a clear path to retire our remaining 2027 and 2028 notes at maturity. With our strong cash generation, we remain focused on capital deployment to maximize long-term value creation."

Recent and Third Quarter Corporate Highlights:

  • In October 2026, the Company announced the specialized Dutch patent court of the Hague found Merck Sharp & Dohme B.V. ("MSD BV"), the central European Market Authorization holder for Merck & Co., Inc., to be infringing one of Halozyme's MDASE™ patents and ordered MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and using, or importing or stocking for these purposes, Keytruda Qlex in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The injunction also forbids MSD BV to facilitate infringement by its affiliates in those countries, including by allowing the use of its European Marketing Authorization. The court also rejected MSD BV's arguments that the patent is invalid.
  • During the third quarter of 2026, Halozyme repurchased approximately 0.8 million shares for $67.2 million at an average price of $79.47 per share under the May 2026 share repurchase program, resulting in $400 million of share repurchases in 2026.

Recent Partner Highlights:

  • In October 2026, Takeda announced a Biologics License Application was filed with the Food and Drug Administration ("FDA") for TAK-881 for the treatment of Primary Immunodeficiency Disease.
  • In October 2026, Janssen expanded its collaboration and licensing agreement with us for an additional oncology target to be developed with ENHANZE®.
  • In October 2026, Roche announced the FDA has approved TECENTRIQ® (atezolizumab) and TECENTRIQ HYBREZA® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair ("dMMR") colon cancer, a type of tumour characterized by high mutation rates. This approval marks the twelfth indication for TECENTRIQ in the U.S.

Third Quarter Partner Highlights:

  • In the third quarter of 2026, argenx submitted a supplemental Biologics License Application for VYVGART® in ocular myasthenia gravis to the FDA.
  • In September 2026, argenx expanded its collaboration and licensing agreement by nominating two additional targets which provides exclusive access to ENHANZE® for a total of eight targets.
  • In September 2026, Pfizer initiated a Phase 1 study to evaluate the pharmacokinetics of a single SC dose of tilrekimig with ENHANZE® in healthy adults. Tilrekimig is a trispecific monoclonal antibody being developed for the treatment of atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
  • In September 2026, Halozyme and Incyte expanded their collaboration to evaluate the SC formulation of axatilimab, a monoclonal antibody targeting colony-simulating factor-1 receptor, with ENHANZE®. Under the terms of the new target agreement, Incyte agreed to make an upfront payment and potential future milestone payments and royalties on net sales of products developed with ENHANZE®.
  • In August 2026, GSK disclosed plans to initiate a Phase 1b study to evaluate the pharmacokinetics and safety of a SC belantamab formulation with ENHANZE® versus IV belantamab in patients with multiple myeloma while treated with standard of care.
  • The SC formulation of INCA033989, a first-in-class mutant calreticulin-targeted monoclonal antibody utilizing ENHANZE® drug delivery technology is being evaluated in an ongoing Phase 1 study.
  • In July 2026, Halozyme and Incyte entered into a global collaboration and license agreement to evaluate additional SC formulations of INCA033989, a first-in-class mutant calreticulin-targeted monoclonal antibody, in patients with mutant calreticulin expressing myeloproliferative neoplasms, utilizing Halozyme's proprietary ENHANZE® drug delivery technology. Under the collaboration, Incyte also has the option to nominate up to two additional targets for use with ENHANZE®. Under the terms of the agreement, Incyte agreed to make an upfront payment and potential future milestone payments and royalties on net sales of products developed with ENHANZE®.
  • In July 2026, Janssen announced the FDA granted priority review of the supplemental Biologics License Application filing for SC amivantamab and hyaluronidase-lpuj in adults with head and neck squamous cell carcinoma.
  • In the third quarter of 2026, the ongoing ARGX-119 adimanebart program was expanded to include a Phase 1 SC bioavailability study with ENHANZE®.

Third Quarter 2026 Financial Highlights:

  • Total revenue was $493.0 million, compared to $354.3 million in the third quarter of 2025. The 39% year-over-year increase was primarily driven by royalty revenue growth and an increase in product sales. Revenue included $341.0 million in royalties, an increase of 44% compared to $236.0 million in the third quarter of 2025, primarily driven by continued sales uptake of ENHANZE® partner products that have launched since 2020, predominantly by VYVGART® Hytrulo by argenx, DARZALEX® SC by Janssen, and Phesgo by Roche in all geographies and contributions from other recently launched products.
  • Cost of sales was $82.5 million, compared to $55.2 million in the third quarter of 2025. The increase in cost of sales was primarily due to an increase in bulk rHuPH20 sales.
  • Amortization of intangibles expense was $29.5 million, compared to $17.8 million in the third quarter of 2025. The increase in amortization of intangibles expense was due to the acquisition of Elektrofi, Inc. ("Elektrofi") in November 2025.
  • Research and development expense was $27.8 million, compared to $17.3 million in the third quarter of 2025. The increase was primarily due to the acquisition of Elektrofi and Surf Bio, Inc. in the fourth quarter of 2025.
  • Selling, general and administrative expense was $58.2 million, compared to $46.1 million in the third quarter of 2025. The increase was primarily due to an increase in consulting and professional service fees, including litigation costs incurred in connection with a patent infringement litigation case, the acquisition of Elektrofi, and an increase in compensation expense.
  • Operating income was $295.0 million, compared to $217.9 million in the third quarter of 2025.
  • Net income was $247.0 million, compared to $175.2 million in the third quarter of 2025.
  • EBITDA was $328.7 million, compared to $238.3 million in the third quarter of 2025. Adjusted EBITDA was $336.2 million, compared to $248.2 million in the third quarter of 2025.1
  • GAAP diluted earnings per share was $2.01, compared to $1.43 in the third quarter of 2025. Non-GAAP diluted earnings per share was $2.39, compared to $1.72 in the third quarter of 2025.1
  • Cash, cash equivalents, restricted cash and marketable securities were $1.08 billion on September 30, 2026, compared to $145.4 million on December 31, 2025. The increase was primarily driven by the issuance of convertible notes and cash generated from operations.

Financial Outlook for 2026

The Company is raising its 2026 financial guidance ranges, which were last updated on August 6, 2026.

For the full year 2026, the Company expects:

  • Total revenue of $1.860 billion to $1.925 billion, representing growth of 33% to 38% over 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API.
  • Revenue from royalties of $1.235 billion to $1.255 billion, representing growth of 42% to 45% over 2025.
  • Adjusted EBITDA of $1.240 billion to $1.290 billion, representing growth of 89% to 96% over 2025, including new Hypercon™ and Aerocon™ investments of approximately $60 million.
  • Non-GAAP diluted earnings per share of $8.75 to $9.05, representing growth of 111% to 118% over 2025. The Company's earnings per share guidance includes new Hypercon™ and Aerocon™ investments of approximately $60 million and does not consider the impact of potential future share repurchases.

Table 1. 2026 Financial Guidance

Previous Guidance Range New Guidance Range
Total Revenue $1.835 to $1.910 billion $1.860 to $1.925 billion
Royalty Revenue $1.220 to $1.245 billion $1.235 to $1.255 billion
Adjusted EBITDA1 $1.225 to $1.280 billion $1.240 to $1.290 billion
Non-GAAP Diluted EPS1 $8.65 to $9.00 $8.75 to $9.05

1 EBITDA, Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See "Note Regarding Use of Non-GAAP Financial Measures" below for an explanation of these measures. Reconciliations between GAAP reported and Non-GAAP financial information for actual results are provided at the end of this earnings release.

Webcast and Conference Call

Halozyme will host its Quarterly Update Conference Call for the third quarter ended September 30, 2026 today, Thursday, November 5, 2026, at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link: https://events.q4inc.com/analyst/811361061?pwd=qhqAVQ9L . The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com .

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology, recently renamed as Aerocon™. Hypercon™ is microparticle technology with the potential to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Aerocon™ polymer-based hyperconcentration technology may further broaden the range of biologics that can be delivered subcutaneously. Together, we believe Hypercon™ and Aerocon™ technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

Prompts

Halozyme Therapeutics, Inc. (ticker HALO), listed in United States.

Company History

Date Change Detail
Mar 17, 2004 Renamed GLOBAL YACHT SERVICES INC → HALOZYME THERAPEUTICS INC

ETFs Holding Halozyme Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
SCAP 3.59% 6,730 $ 716.678K Aug 31, 2026
FFLS 3.46% 14,043 $ 1.495M Aug 31, 2026
LSAT 3.43% 26,416 $ 2.18M Jul 31, 2026
FFOX 3.20% 98,193 $ 7.686M Jun 30, 2026
CANC 3.19% 63,165 $ 6.726M Aug 31, 2026
CSMD 2.87% 157,971 $ 13.039M Jul 31, 2026
FCUS 2.60% 20,076 $ 1.937M Nov 17, 2026
JMID 1.93% 5,526 $ 456.116K Jul 31, 2026
SSMG 1.86% 720 $ 59.429K Jul 31, 2026
BMED 1.70% 2,531 $ 244.242K Nov 16, 2026
FFND 1.65% 15,313 $ 1.631M Aug 31, 2026
ALIL 1.33% 2,852 $ 270K Nov 18, 2026
BRES 1.31% 82,922 $ 7.96M Nov 18, 2026
SMRI 1.25% 90,312 $ 8.67M Nov 18, 2026
JSMD 1.18% 150,450 $ 12.418M Jul 31, 2026
NBSM 1.01% 10,909 $ 1.162M Aug 31, 2026
LSEQ 0.90% 1,589 $ 159.329K Nov 13, 2026
AFMC 0.88% 23,929 $ 2.309M Nov 16, 2026
ROE 0.88% 22,767 $ 2.18M Nov 18, 2026
SURE 0.84% 5,033 $ 483.017K Nov 17, 2026
MMSC 0.77% 4,011 $ 387.062K Nov 16, 2026
CLSE 0.74% 62,247 $ 6.629M Aug 31, 2026
ILDR 0.70% 23,116 $ 2.231M Nov 16, 2026
SAWS 0.69% 652 $ 53.816K Jul 31, 2026
BRNY 0.64% 37,039 $ 3.55M Nov 18, 2026
GQQQ 0.63% 10,738 $ 1.03M Nov 18, 2026
AFSM 0.62% 9,345 $ 901.793K Nov 16, 2026
HWSM 0.62% 217 $ 16.985K Jun 30, 2026
SMDX 0.57% 7,493 $ 723.075K Nov 17, 2026
FEMG 0.45% 385 $ 30.134K Jun 30, 2026
JMEE 0.43% 128,721 $ 12.353M Nov 17, 2026
SCDS 0.42% 403 $ 38.676K Nov 17, 2026
EHLS 0.33% 1,828 $ 176.402K Nov 17, 2026
SMIZ 0.29% 7,557 $ 804.745K Aug 31, 2026
LSVD 0.24% 18,498 $ 1.527M Jul 31, 2026
DFAS 0.19% 639,588 $ 64.387M Nov 12, 2026
SXQG 0.19% 1,125 $ 113.254K Nov 12, 2026
GVLU 0.19% 5,130 $ 495.045K Nov 17, 2026
MKTN 0.19% 2,571 $ 201.232K Jun 30, 2026
FSCC 0.19% 6,402 $ 681.749K Aug 31, 2026
WCEO 0.17% 207 $ 17.086K Jul 31, 2026
VFMO 0.15% 27,278 $ 2.905M Aug 31, 2026
SEIS 0.15% 10,978 $ 859.248K Jun 30, 2026
AVMC 0.14% 8,097 $ 781.361K Nov 16, 2026
TMSL 0.12% 41,471 $ 3.246M Jun 30, 2026
AVIE 0.12% 202 $ 19.493K Nov 16, 2026
FTLS 0.12% 32,364 $ 0.00 Nov 16, 2026
AVSU 0.07% 3,319 $ 320.284K Nov 16, 2026
REMC 0.06% 28 $ 2,191.56 Jun 30, 2026
MSSM 0.06% 4,284 $ 456.203K Aug 31, 2026
DXUV 0.06% 37,524 $ 3.778M Nov 12, 2026
AVUQ 0.05% 2,318 $ 223.687K Nov 16, 2026
DFSU 0.04% 9,964 $ 1.003M Nov 12, 2026
VSLU 0.04% 2,916 $ 228.235K Jun 30, 2026
DFAC 0.04% 354,807 $ 35.718M Nov 12, 2026
AVLC 0.04% 5,908 $ 570.122K Nov 16, 2026
DYNF 0.04% 172,140 $ 16.612M Nov 16, 2026
FMDE 0.04% 36,965 $ 2.893M Jun 30, 2026
AVUS 0.03% 43,039 $ 4.153M Nov 16, 2026
IALT short -0.03% -26,503 $ -2.558M Nov 16, 2026
DFAU 0.02% 29,433 $ 2.963M Nov 12, 2026
DFUS 0.02% 37,111 $ 3.736M Nov 12, 2026
EBI 0.02% 1,106 $ 117.778K Aug 31, 2026
DCOR 0.02% 73,542 $ 7.403M Nov 12, 2026
MSLC 0.01% 4,466 $ 475.584K Aug 31, 2026
NTRL 0.00% 1,778 $ 0.00 Nov 16, 2026